Mesoblast Limited

On Wednesday 22 September 2010, Mesoblast Limited (ASX:MSB) (PINK:MBLTY) will hold an Extraordinary General Meeting of shareholders to consider a proposed acquisition of its United States-based associate company, Angioblast Systems Inc. This is a key event in your Company's evolution.

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today provided market guidance on its Phase 3 bone marrow transplant program following a formal meeting with the United States Food and Drug Administration (FDA).

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the Australian Therapeutic Goods Administration (TGA) has issued a licence to Mesoblast to manufacture and supply its proprietary Mesenchymal Precursor Cells (MPC) products.

Australian regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that based on positive results from its bone marrow transplant clinical trial, conducted at the University of Texas MD Anderson Cancer Center, a formal meeting has been scheduled with the United States Food and Drug Administration (FDA) to discuss a proposed Phase 3 clinical trial program.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (ADR:MBLTY), was featured yesterday by the ASX at its inaugural Small to Mid Caps Conference in Singapore.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (ADR:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration (FDA) to begin Phase 2 clinical trials of its "off-the-shelf" or allogeneic stem cell product NeoFuse(TM) for fusion of the cervical spine in the neck. As with all of Mesoblast's previous Investigational New Drug (IND) submissions, FDA clearance was obtained within the minimum 30-day period.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (OTC:MBLTY) today announced that it will acquire its United States associate company, Angioblast Systems, Inc. (Angioblast). Additionally, Mesoblast announced it has completed a capital raising of A$37 million to fund the acquisition and advance operations of the expanded Mesoblast Group. These funds comprise A$24 million invested immediately and A$13 million committed subject to both shareholder approval and completion of the acquisition offer.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (ADR:MBLTY),today announced it had cash reserves of $12.6 million for the reporting period ended 31 March 2010. The results are in line with expectations and reflect prudent cash management and tight control of resources.

Australian regenerative medicine company and biologic innovator, Mesoblast Limited (ASX:MSB) (OTC:MBLTY), today provided an assessment on how the recently enacted United States Patient Protection and Affordable Care Act (HB 3590) is expected to have a positive impact on the commercial prospects for both Mesoblast and its United States-associated company, Angioblast Systems Inc.

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), today announced that the United States Patent and Trademark Office (USPTO) has granted a key patent that provides exclusive commercial protection for its bone tissue generating products through to at least the year 2019 in the United States, the world's largest market for regenerative medicines.